MCC has no treatment option, no standard of care, and nothing in clinical development. ONCS has no competition in this space, and if it shows the slightest benefit in increasing life or delaying progression, it will be FDA approved. Then, ONCS would create $200-$300 million from this one indication. For such a small company, this one catalyst could send shares higher by 1,000%. And we haven't even looked at its other programs.
I think you spot on janet. And I think there will be immediate carry-over to Oncosec's melanoma and lymphoma trials and their potential revenue generation which could drive PPS beyond the 1000% analyst projection. I also think MCC can provide the needed impetus for partnering, creating additional pressure upward.
I think this is an interesting topic that sometimes gets overlooked. If data is good there will be no need for additional testing, and MCC could be producing revenue by early 2015. Just look at SRPT, it's likely going to get an approval early next year, and on a dozen patients.